KALV
Kalvista Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.03B
P/E Ratio
—
EPS
$-3.94
Beta
-0.40
52W High
$21.30
52W Low
$9.83
50-Day MA
$16.47
200-Day MA
$14.34
Dividend Yield
—
Profit Margin
-223.20%
Forward P/E
18.76
PEG Ratio
0.00
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $73.62M |
| Gross Profit (TTM) | $18.94M |
| EBITDA | $-164.82M |
| Operating Margin | -21.20% |
| Return on Equity | -190.20% |
| Return on Assets | -61.00% |
| Revenue/Share (TTM) | $1.37 |
| Book Value | $-0.05 |
| Price-to-Book | 49.03 |
| Price-to-Sales (TTM) | 14.00 |
| EV/Revenue | 610.58 |
| EV/EBITDA | -3.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 30.70% |
| Shares Outstanding | $51.22M |
| Float | $27.92M |
| % Insiders | 1.61% |
| % Institutions | 134.63% |
Analyst Ratings
Consensus ($34.33 target)
2
Strong Buy7
BuyData last updated: 4/8/2026